Two Side Effects of Sutent Therapy in Renal Cell Carcinoma: A Case Report

Introduction Renal cell carcinoma (RCC) has known as the most frequent urological malignancy among adults, which occured mostly among male patients. Sunitinib malate (SUTENT^®, Pfizer Inc., New York, NY, USA) is an oral, multitargeted tyrosine kinase inhibitor (TKI) which acts on VEGF receptors 1–3. Herein, we have presented two simultaneous adverse effects (nail changes and erythematous lesions over the knuckles) of 26-year-young woman with a high risk RCC during the sunitinib therapy. Case Presentation Our patient was a 26-year-young woman, who has undergone left radical nephrectomy in December 2013. Microscopic pathological analysis has shown a 40 mm clear cell carcinoma of grade 2. She has started on target therapy with sunitinib, at over 3 months of TKI Sutent 50 mg four weeks on and two weeks off in this drug. We have seen, nails changes and erythematous lesions over the knuckles. After decreasing the dosage of the drug to 12.5 mg four weeks on and two weeks off the severity of lesions have decreased and subside the complaints of patients. Conclusions Sunitinib therapy could have different side effects among patients. We have not known that a benign side effect could affect a female patient like discoloration despite, or not. This matter that you had not any interference for its treatment, but it has exited so we must try to know more about it.